133 results on '"Boccadoro M."'
Search Results
2. A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma
3. Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma
4. Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival
5. Circulating miRNA markers show promise as new prognosticators for multiple myeloma
6. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders
7. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia
8. Lenalidomide−prednisone induction followed by lenalidomide−melphalan−prednisone consolidation and lenalidomide−prednisone maintenance in newly diagnosed elderly unfit myeloma patients
9. Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy
10. IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells
11. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
12. Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma
13. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
14. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
15. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation
16. Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia
17. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
18. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study
19. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
20. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)
21. Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients
22. Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial
23. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
24. Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside
25. Effector γδ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma
26. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy
27. Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2)
28. Lenalidomide — prednisone induction followed by lenalidomide — melphalan — prednisone consolidation and lenalidomide — prednisone maintenance in newly diagnosed elderly unfit myeloma patients
29. Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma
30. Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma
31. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors
32. BRAF gene is not mutated in plasma cell leukemia and multiple myeloma
33. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network
34. Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma
35. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis
36. Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma
37. Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival
38. Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma
39. Extracellular vesicles as potential biomarkers of acute graft-vs-host disease
40. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders
41. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia
42. Lenalidomide−prednisone induction followed by lenalidomide−melphalan−prednisone consolidation and lenalidomide−prednisone maintenance in newly diagnosed elderly unfit myeloma patients
43. Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2)
44. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy
45. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia
46. Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.
47. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).
48. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network.
49. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN).
50. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.